Savaysa FDA Approval History
FDA Approved: Yes (First approved January 8, 2015)
Brand name: Savaysa
Generic name: edoxaban
Dosage form: Tablets
Company: Daiichi Sankyo Inc.
Treatment for: Prevention of Thromboembolism in Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism
Savaysa (edoxaban) is an oral, once-daily factor Xa inhibitor anticoagulant indicated for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment of deep vein thrombosis, and pulmonary embolism.
Development timeline for Savaysa
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.